Logo

LNAI

Lunai Bioworks Inc.

LNAI

Lunai Bioworks Inc. • NASDAQ
$1.18 ▼ -8.53% (-0.11)
Market Cap $21.00 M
52w High $21.00
52w Low $0.81
Dividend Yield 0%
P/E -0.15
Volume 425.61K
Outstanding Shares 17.80M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q1-2025 $0 $2.435M ▼ $2.819M ▲ 0% $0.13 ▲ $2.983M ▲
Q4-2024 $0 $126.919M ▲ $-126.732M ▼ 0% $-7.61 ▼ $-126.512M ▼
Q3-2024 $0 $4.162M ▼ $189.176K ▲ 0% $0.012 ▲ $409.836K ▲
Q2-2024 $0 $4.546M ▼ $-7.252M ▲ 0% $-0.4 ▲ $-7.104M ▲
Q1-2024 $0 $53.339M $-44.212M 0% $-2.8 $-43.93M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q1-2025 $624.808K ▲ $6.961M ▼ $20.001M ▼ $-13.041M ▲
Q4-2024 $480.551K ▼ $8.231M ▼ $29.581M ▲ $-21.35M ▼
Q3-2024 $1.633M ▲ $117.726M ▲ $29.339M ▲ $88.387M ▲
Q2-2024 $311.764K ▲ $111.34M ▼ $29.281M ▲ $82.059M ▼
Q1-2024 $220.571K $121.833M $23.746M $98.087M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q1-2025 $2.819M ▲ $-1.349M ▲ $544.7K ▼ $1.343M ▲ $532.108K ▲ $-1.349M ▲
Q4-2024 $-126.732M ▼ $-1.811M ▼ $964.389K ▲ $178.357K ▼ $-830.302K ▼ $-1.811M ▼
Q3-2024 $189.176K ▲ $-1.487M ▲ $-1.464M ▼ $3.584M ▲ $611.238K ▲ $-1.487M ▲
Q2-2024 $-7.252M ▲ $-2.56M ▼ $0 $2.591M ▲ $91.193K ▲ $-2.56M ▼
Q1-2024 $-44.212M $-2.016M $0 $2.029M $104 $-2.016M

Five-Year Company Overview

Income Statement

Income Statement Lunai is still a pure research-stage company: it has no product sales and all of its reported activity is costs, mainly R&D and corporate overhead. Losses have been steady and are growing as the company scales up its scientific and AI efforts. The absolute size of the loss is still relatively small for the sector, but it is meaningful given how small the company is. Profitability is not in sight yet; any improvement will depend on either partnerships and licensing income or a very disciplined control of spending while it advances the pipeline.

Balance Sheet

Balance Sheet The balance sheet is very thin, reflecting an early-stage biotech with limited resources. Total assets are modest, cash has been minimal, and a small amount of debt has appeared recently. Equity has swung from positive to slightly negative, which means obligations now slightly exceed reported assets and leaves little financial cushion. Overall, the company looks financially fragile and heavily dependent on future capital raises or deals to support its plans.

Cash Flow

Cash Flow Cash flow is consistently negative, driven by operating expenses for research and corporate functions. The cash burn so far has been modest in absolute terms and the company has not been spending heavily on physical infrastructure or equipment, which keeps investment needs lighter. However, there is no incoming cash from operations, so the business is entirely reliant on external funding sources. As the pipeline moves toward clinical trials, cash needs are likely to rise, which could increase funding pressure.

Competitive Edge

Competitive Edge Competitively, Lunai is trying to differentiate itself by combining an “off‑the‑shelf” dendritic cell therapy platform with an AI-driven discovery and safety engine. The cell therapy approach, if it works in humans as it has in early preclinical models, could offer a more scalable and potentially more accessible alternative to patient-specific cell therapies. Its AI platform, backed by proprietary toxicity and patient datasets, may provide a defensible data advantage and positions the company in both drug discovery and biodefense niches. At the same time, Lunai is very small and preclinical in a crowded field dominated by large pharma, established cell therapy players, and well-funded AI drug discovery firms, so its real competitive strength will only be proven through clinical results and meaningful partnerships.

Innovation and R&D

Innovation and R&D Innovation is clearly the core of Lunai’s story. The company is advancing allogeneic dendritic cell vaccines for hard‑to‑treat cancers, with eye‑catching preclinical data in pancreatic cancer and a broader solid-tumor strategy. In parallel, its BioSymetrics and Elion platforms use AI and rich proprietary datasets for target discovery, patient stratification, and safety screening, and extend into neurodegenerative diseases and biodefense. These programs are still early, mostly preclinical or in preparation for first‑in‑human trials, so scientific and regulatory risk is high, but the technology mix is ambitious and differentiated compared with many single‑asset biotechs.

Summary

Lunai Bioworks is an early-stage, high‑risk biotech centered on an allogeneic cell therapy platform and an AI-enabled discovery and safety engine, with no commercial products yet and no revenue to date. Financially, it operates on a very small base with thin reserves, persistent losses, and ongoing negative cash flow, leaving it reliant on equity raises, grants, and partnering deals to fund its growth. Strategically, the company’s edge lies in potentially scalable “off‑the‑shelf” immunotherapies, proprietary AI tools, and dual-use opportunities in oncology, neurology, and biodefense, but all of this remains to be validated in human clinical trials. The investment case revolves around whether Lunai can turn promising preclinical and AI capabilities into credible clinical data and durable partnerships before its limited financial runway becomes a constraint.

NEWS

November 25, 2025 · 7:45 AM UTC

Lunai Bioworks Secures First Licensing LOI Following Landmark Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models

Read more

November 5, 2025 · 9:22 AM UTC

Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer immunotherapy

Read more

October 30, 2025 · 9:32 AM UTC

Lunai Bioworks Harnesses AI and Zebrafish Data to Advance Early Detection of Neurotoxic Compounds

Read more

October 16, 2025 · 9:45 AM UTC

Landmark Study Identifies Prognostic Biomarkers in Duchenne Muscular Dystrophy Using Large-Scale Serum Proteomics

Read more

October 16, 2025 · 9:15 AM UTC

Lunai Bioworks Regains Compliance with Nasdaq Minimum Bid Price Requirement

Read more